New York, June 3, 2026, 12:12 (EDT)
Silexion Therapeutics Corp shares slipped 14 cents to $4.85 in midday Nasdaq trading on Wednesday, leaving the cancer-drug developer lower even as biotech exchange-traded funds gained. The stock had traded between $4.69 and $5.04 on volume of about 78,000 shares.
The move matters because Silexion is only days into trading on a split-adjusted basis after a 1-for-10 reverse share split, a step that combines shares to lift the quoted price without changing an investor’s proportional ownership. The company said the action was aimed at helping it maintain compliance with Nasdaq requirements and support development of SIL204, its lead pancreatic-cancer candidate.
A filing showed the reverse split became effective after the close on May 28, with trading on the adjusted basis starting May 29 under the same ticker, SLXN. The filing also showed the company’s ordinary-share CUSIP changed to G1281K148.
Nasdaq’s corporate-actions notice separately listed the one-for-ten split and par-value change from $0.0135 to $0.135 as effective on May 29. Nasdaq was open for regular trading on Wednesday; its listed 2026 market holidays do not include June 3, and regular hours run from 9:30 a.m. to 4:00 p.m. Eastern time.
Chairman and Chief Executive Ilan Hadar called the split a “deliberate step to preserve our Nasdaq listing” and said Silexion wanted to approach the planned Phase 2/3 trial from “a position of strength” in public markets. The same release said SIL204 targets locally advanced pancreatic cancer.
That is the stock story now: less about one intraday tick, more about whether a small clinical-stage company can keep its listing, raise money and start the study it has promised. Silexion has said SIL204 is a small interfering RNA, or siRNA, a type of molecule designed to block production of a disease-related protein, aimed at mutated KRAS, a cancer driver common in pancreatic tumors.
The company reported a first-quarter net loss of about $2.7 million, up from $1.7 million a year earlier, as research and development spending more than doubled to about $1.4 million. Cash and cash equivalents stood at $2.4 million at March 31, while the company said a May warrant exercise inducement brought in about $1.0 million in gross proceeds.
Silexion has said Israel’s Ministry of Health approved the start of a Phase 2/3 trial, and that it submitted a clinical-trial application in Germany through the European Union system. The planned study is expected to begin in the second quarter with an initial safety run-in of about 18 patients, followed by a randomized cohort of about 166 patients.
Chief Financial Officer Mirit Horenshtein Hadar said last month the company had used capital-raising and corporate actions to support its clinical plan and Nasdaq listing. “We continue to evaluate financing alternatives,” she said. GlobeNewswire
Silexion’s weaker move came against a firmer biotech tape. The iShares Nasdaq Biotechnology ETF was up about 1.2%, while the SPDR S&P Biotech ETF rose about 1.0%, suggesting the pressure on SLXN was more company-specific than sector-wide by midday.
The competitive backdrop also sharpened this week. Revolution Medicines, another KRAS-focused cancer-drug developer, rose about 1.9% on Wednesday after Reuters reported that its experimental pancreatic-cancer pill daraxonrasib doubled survival versus chemotherapy in a 500-person trial and cut the overall risk of death by 60%. The settings and mechanisms differ, but the data raise the bar for investors looking at KRAS-linked pancreatic-cancer programs.
Dr. Rachna Shroff of the University of Arizona Cancer Center, an ASCO pancreatic-cancer expert, told Reuters the Revolution data “ticks all of the boxes.” Dr. Brian Wolpin of Dana-Farber, the trial’s principal investigator, said the results would change how the field thinks about pancreatic-cancer treatment. Reuters
But a reverse split does not supply clinical data, cash or regulatory clearance. Silexion’s own cautionary language points to risks around whether it can start and run the SIL204 trial, secure capital, manage regulatory reviews and continue meeting Nasdaq listing standards; thin trading can also make price moves sharper in either direction.
The next hard markers are concrete ones: a confirmed trial start, any update on Germany and EU review, further financing disclosures and Nasdaq compliance notices. Until then, the share price is trading on structure, liquidity and belief in a clinical plan that still has to be executed.
